Enrollment completed in phase 1 influenza a study with cocrystal pharma's oral antiviral candidate cc-42344

Bothell, wash., oct. 26, 2022 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) announces the completion of enrollment in a phase 1 healthy volunteer study to assess the safety, tolerability and pharmacokinetics (pk) of its orally administered, novel, broad-spectrum antiviral candidate cc-42344 for the treatment of pandemic and seasonal influenza a. cc-42344 represents a new class of antiviral treatment designed to block an essential step in the viral replication and transcription of pandemic and seasonal influenza a.
COCP Ratings Summary
COCP Quant Ranking